Hu Xingyao, Shang Guangbin, Zhang Jie, Chen Zhong, Fu Liu, Li Jun, Lu Xiaonan
Research Center for Differention and Development of TCM Basic Theory.
The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine.
Medicine (Baltimore). 2021 Apr 2;100(13):e24530. doi: 10.1097/MD.0000000000024530.
At present, Liver Cirrhosis (LC) is common in most later liver and gallbladder diseases that its morbidity and mortality seriously affect human health. The limitation and effectiveness of western medicine on LC have become a huge clinical challenge. However, a large number of clinical studies have shown that Yi-guan decoction has become a complementary treatment for LC. Therefore, this systematic review will aim to explore the safety and feasibility of Yi-guan decoction in the treatment of LC.
We will conduct a comprehensive literature search in Medline, PubMed, Cochrane Database of Systematic Reviews, Embase, Chinese Biomedical Literatures Database, China National Knowledge Infrastructure, Wang Fang Database, Chinese Scientific Journal Database from inception to December 2020 without any language restriction, In addition, relevant literature will be searched manually. The main subject terms searched: "Yi-guan decoction" "cirrhosis" "LC". Data entry will be performed by 2 researchers separately. Primary outcomes will be concluded: Liver function indicators: Total bilirubin, Alanine transaminase, Aspartate aminotransferase, etc. Secondary outcome indicators: Total effective rate, Nutrition index, Survival analysis, Adverse events; All randomized controlled trials collected in this study will be evaluated and rated using the Cochrane risk-of-biasassessment tool. Meta-analysis will be performed using RevMan 5.4.0 software. The heterogeneity test will be conducted between the studies, P < .1 and I2 > 50% are the thresholds for the tests. Using solid effect model or random effect model will be based on its heterogeneity value.
This systematic review provides a theoretical basis for Yi-guan decoction to treat LC, we will report this result soon.
This study will explore Yi-guan decoction can will be used as one of the non drug therapies to prevent or treat LC.
INPLASY2020120114.
目前，肝硬化（LC）在大多数晚期肝脏和胆囊疾病中很常见，其发病率和死亡率严重影响人类健康。西医治疗LC的局限性和有效性已成为巨大的临床挑战。然而，大量临床研究表明，一贯煎已成为LC的辅助治疗方法。因此，本系统评价旨在探讨一贯煎治疗LC的安全性和可行性。
我们将在Medline、PubMed、Cochrane系统评价数据库、Embase、中国生物医学文献数据库、中国知网、万方数据库、维普数据库中进行全面的文献检索，检索时间从建库至2020年12月，无语言限制。此外，还将手动检索相关文献。检索的主要主题词为：“一贯煎”“肝硬化”“LC”。数据录入将由2名研究人员分别进行。主要结局指标包括：肝功能指标：总胆红素、谷丙转氨酶、谷草转氨酶等。次要结局指标：总有效率、营养指标、生存分析、不良事件；本研究收集的所有随机对照试验将使用Cochrane偏倚风险评估工具进行评估和评级。将使用RevMan 5.4.0软件进行荟萃分析。将在各研究之间进行异质性检验，检验阈值为P<0.1和I2>50%。将根据异质性值使用固定效应模型或随机效应模型。
本系统评价为一贯煎治疗LC提供了理论依据，我们将尽快报告这一结果。
本研究将探讨一贯煎能否作为预防或治疗LC的非药物疗法之一。
INPLASY2020120114。
